Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angels Share In Biotech Rewards, But Rarely In Drug Discovery

This article was originally published in The Pink Sheet Daily

Executive Summary

New data shows an uptick in start-up investment by individuals in young biotech and health care companies, as the contracting venture capital industry shies away from early-stage investing. But angels still avoid companies with high costs, particularly those associated with clinical and regulatory paths.

You may also be interested in...



Corporate Venture Eyes The Early Stage

In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.

Acetylon Pharmaceuticals Inc.

There are a number of histone deacetylase inhibitors on the market and in development that regulate gene expression in normal as well as cancer cells but can lead to a number of serious side effects. Acetylon Pharmaceuticals Inc. is developing small-molecule compounds that selectively inhibit HD AC for the treatment of cancers as well as inflammatory neurodegenerative, genetic and infectious disease.

Biotech Angels Are Going Where VCs Fear To Tread

Many VCs have lost interest in early-stage investing, but angels - individuals who invest their own money alone or in groups - are stepping up to fill the gap. Angels are an especially good fit for for biotech start-ups that don't want to cede control of their companies to VCs too early, if at all. In addition to bringing valuable cash, angels put less pressure on start-ups to achieve an exit within a given time frame than traditional venture investors, and are more willing to accept buyers that may not be the highest bidders but will nevertheless be good stewards for their assets. For their part, companies looking to angels must understand the goals of their potential backers, since these financiers are often motivated by philanthropy and personal interest in a disease.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS073355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel